Intellia: FDA Accepts NTLA-5001 IND in Acute Myeloid Leukemia

By Colin Kellaher

Intellia Therapeutics Inc. on Thursday said the U.S. Food and Drug Administration has accepted its investigational new drug application for NTLA-5001 in acute myeloid leukemia, a cancer of the blood and bone marrow.

The Cambridge, Mass., clinical-stage genome-editing company said NTLA-5001 would be its first ex-vivo candidate using its proprietary cell-engineering process for the treatment of cancer to enter clinical studies.

Intellia said it plans to begin patient screening by the end of the year for a Phase 1/2a study evaluating NTLA-5001 in adults with persistent or recurrent acute myeloid leukemia who have previously received first-line therapy.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 16, 2021 08:01 ET (12:01 GMT)

Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024